Patents by Inventor Ehab Khalil
Ehab Khalil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150072997Abstract: The present invention provides tricyclic compounds, arylamide compounds, and other compounds, and compositions comprising the same, for treating malaria, and methods of treating malaria comprising administering such compounds to an animal.Type: ApplicationFiled: August 5, 2014Publication date: March 12, 2015Inventors: Richard W. Scott, Doron Greenbaum, Dahui Liu, Xiaodong Fan, Yongjiang Xu, Haizhong Tang, Ehab Khalil
-
Patent number: 8796275Abstract: The present invention provides tricyclic compounds, arylamide compounds, and other compounds, and compositions comprising the same, for treating malaria, and methods of treating malaria comprising administering such compounds to an animal.Type: GrantFiled: July 28, 2009Date of Patent: August 5, 2014Assignees: The Trustees of the University of Pennsylvania, Cellceutix CorporationInventors: Richard W. Scott, Doron Greenbaum, Dahui Liu, Xiaodong Fan, Yongjiang Xu, Haizhong Tang, Ehab Khalil
-
Publication number: 20120115877Abstract: The present invention discloses compositions of facially amphiphilic compounds and their use in methods for treating or reducing cancers in animals, such as humans.Type: ApplicationFiled: August 20, 2011Publication date: May 10, 2012Applicant: POLYMEDIX, INC.Inventors: Richard W. Scott, Dylan Clements, Yongjiang Xu, Haizhong Tang, Carol Mulrooney, Ehab Khalil, Damian Weaver, Xiaodong Fan
-
Patent number: 8173654Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: August 7, 2008Date of Patent: May 8, 2012Assignee: Janssen Pharmaceutica N.V.Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
-
Patent number: 8030305Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: December 18, 2006Date of Patent: October 4, 2011Assignee: Janssen Pharmaceutica N.V.Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
-
Publication number: 20100081665Abstract: The present invention provides tricyclic compounds, arylamide compounds, and other compounds, and compositions comprising the same, for treating malaria, and methods of treating malaria comprising administering such compounds to an animal.Type: ApplicationFiled: July 28, 2009Publication date: April 1, 2010Inventors: Richard W. Scott, Doron Greenbaum, Dahui Liu, Xiaodong Fan, Yongjiang Xu, Haizhong Tang, Ehab Khalil
-
Publication number: 20090098181Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: August 7, 2008Publication date: April 16, 2009Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
-
Patent number: 7482376Abstract: The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.Type: GrantFiled: June 16, 2004Date of Patent: January 27, 2009Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Farah Ali, Heather Rae Hufnagel, Shelley Ballentine, Jeremy M. Travins, Kristi A. Leonard, Roger F. Bone
-
Publication number: 20070203136Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: December 18, 2006Publication date: August 30, 2007Inventors: Tianbao Lu, Richard Alexander, Richard Connors, Maxwell Cummings, Robert Galemmo, Heather Rae Hufnagel, Dana Johnson, Ehab Khalil, Kristi Leonard, Thomas Markotan, Anna Maroney, Jan Sechler, Jeremy Travins, Robert Tuman
-
Publication number: 20070066667Abstract: Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specification, as are A Z, Q, R1 and R2.Type: ApplicationFiled: March 14, 2006Publication date: March 22, 2007Inventors: Nalin Subasinghe, Shelley Ballentine, Jeremy Travins, Ehab Khalil, Farah Ali, Kristi Leonard, Joan Gushue, Michael Winters, Heather Hufnagel, Maxwell Cummings
-
Patent number: 7138530Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.Type: GrantFiled: May 28, 2003Date of Patent: November 21, 2006Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Kristi A. Leonard, Farah Ali, Heather Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, Jonathan M. Rudolph, Hui Huang
-
Patent number: 7109354Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.Type: GrantFiled: May 28, 2003Date of Patent: September 19, 2006Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M. Jonathan Rudolph, Hui Huang
-
Publication number: 20050234081Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.Type: ApplicationFiled: May 28, 2003Publication date: October 20, 2005Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Hufnagel, Jeremy Travins, Shelley Ballentine, Kenneth Wilson, Maxwell Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen
-
Publication number: 20050004031Abstract: The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.Type: ApplicationFiled: June 16, 2004Publication date: January 6, 2005Inventors: Nalin Subasinghe, Ehab Khalil, Farah Ali, Heather Hufnagel, Shelley Ballentine, Jeremy Travins, Kristi Leonard, Roger Bone
-
Publication number: 20040009995Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1Type: ApplicationFiled: May 28, 2003Publication date: January 15, 2004Applicant: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M. Jonathan Rudolph, Hui Huang
-
Patent number: 5990094Abstract: This invention is directed to a compound having the formula I. ##STR1## This invention is directed to a pharmaceutical composition comprising a compound which inhibits serotonin N-acetyltransferase having the formula I and a pharmaceutical acceptable carrier. The present invention relates to novel compounds and analogs which inhibit the serotonin N-acetyltransferase enzyme, and to processes for their preparation.Type: GrantFiled: January 27, 1998Date of Patent: November 23, 1999Assignee: The Rockefeller UniversityInventors: Philip A. Cole, Ehab Khalil